瑞舒伐他汀与辛伐他汀治疗缺血性脑卒中的疗效比较

Comparision of Efficacy of Rosuvastatin and Simvastatin for Ischemic Stroke

目的:比较瑞舒伐他汀与辛伐他汀治疗缺血性脑卒中的疗效。方法:选择天津市环湖医院2009年9月-2010年9月确诊的缺血性脑卒中患者150例,随机分为2组。瑞舒伐他汀组76例,给予口服瑞舒伐他汀10mg,qd;辛伐他汀组74例,给予口服辛伐他汀20mg,qd。比较治疗前与治疗3个月后患者空腹静脉血中总胆固醇(TC)、甘油三酯(TG)、低密度脂蛋白胆固醇(LDL-C)、高密度脂蛋白胆固醇(HDL-C)及超敏C反应蛋白(hs-CRP)的变化。观察2组患者的不良反应。结果:治疗后,2组TC、TG、LDL-C、hs-CRP水平均显著低于治疗前,HDL-C水平显著高于治疗前,且瑞舒伐他汀组变化幅度更大,差异均有统计学意义(P<0.05)。瑞舒伐他汀组与辛伐他汀组的缺血性脑卒中复发率分别为7.89%(6/76)和18.92%(14/74),2组比较差异有统计学意义(P=0.047)。2组不良反应均较轻微,且差异无统计学意义(P>0.05)。结论:瑞舒伐他汀与辛伐他汀对于缺血性脑卒中患者均有很好的降脂及抗炎作用,且不良反应发生情况类似,但瑞舒伐他汀效果更为显著且复发率更低。

OBJECTIVE： To compare clinical efficacy of rosuvastatin and simvastatin on ischemic stroke. METHODS： 150 hos- pitalized ischemic stroke patients were selected from our hospital during Sep. 2009- Sep. 2010. 76 patients in rosuvastatin group were given oral dose of rosuvastatin 10 mg, qd; 74 patients in simvastatin group were given oral dose of simvastatin 20 nag, qd. The changes of TC, TG, LDL-C, HDL-C and hs-CRP in fasting venous blood were compared before and after 3 months treatment. RESULTS： Rosuvastatin group and simvastatin group had no significant difference in lipid level and hs-CRP before treatment （all P〉0.05） ; TC, TG, LDL-C and hs-CRP were significantly lowered after treatment, HDL-C level was significantly increased after treatment, and rosuvastatin group had greater changes （all P〈0.05）. The ischemic stroke recurrence rates of rosuvastatin group and simvastatin group were 7.89% （6/76） and 18.92% （14/74）, respectively. That of rosuvastatin group was significantly lower than that of simvastatin group （P=0.047）. The adverse drug reactions of 2 groups were mild relatively, there was no statistical signifi- cance （P〉0.05）. CONCLUSIONS： Both of rosuvastatin and simvastatin have good lipid-lowering and anti-inflammatory effects on ischemic stroke patients, and the incidence of adverse drug reactions are similar between 2 groups. However, rosuvastatin is more effective with lower recurrence rate.